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The iron regulatory hormone hepcidin limits iron fluxes to the bloodstream by promoting
degradation of the iron exporter ferroportin in target cells. Hepcidin insufficiency
causes hyperabsorption of dietary iron, hyperferremia and tissue iron overload, which
are hallmarks of hereditary hemochromatosis. Similar responses are also observed
in iron-loading anemias due to ineffective erythropoiesis (such as thalassemias,
dyserythropoietic anemias andmyelodysplastic syndromes) and in chronic liver diseases.
On the other hand, excessive hepcidin expression inhibits dietary iron absorption and
leads to hypoferremia and iron retention within tissue macrophages. This reduces
iron availability for erythroblasts and contributes to the development of anemias with
iron-restricted erythropoiesis (such as anemia of chronic disease and iron-refractory
iron-deficiency anemia). Pharmacological targeting of the hepcidin/ferroportin axis may
offer considerable therapeutic benefits by correcting iron traffic. This review summarizes
the principles underlying the development of hepcidin-based therapies for the treatment
of iron-related disorders, and discusses the emerging strategies for manipulating
hepcidin pathways.
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INTRODUCTION
Iron is an essential constituent of hemoglobin, myoglobin and several other proteins, but also
potentially toxic due to its redox reactivity that promotes oxidative stress (Papanikolaou and
Pantopoulos, 2005). Balanced iron homeostasis is required to satisfy metabolic needs andminimize
the risk of toxic side effects. More than two thirds of body iron (3–5 g in adults) is used in
hemoglobin of red blood cells (RBCs) (Gkouvatsos et al., 2012). Erythroblasts require a daily
supply of∼20–30mg and non-erythroid cells another∼5mg of iron, which is provided by plasma
transferrin (Figure 1). The transferrin iron pool does not exceed ∼3mg at steady state and turns
over >10 times/day. It is mostly replenished with iron recycled from senescent RBCs by tissue
macrophages. The contribution of dietary iron absorption (1–2 mg/day) is minimal in healthy
individuals, and mostly compensates for non-specific iron losses due to cell desquamation or
bleeding. Iron stored in hepatocytes can be mobilized for erythropoiesis under conditions of iron
deficiency.
Iron eﬄux to the bloodstream is physiologically restrained by hepcidin, an antimicrobial peptide
and master hormonal regulator of systemic iron metabolism (Ganz, 2013). Hepcidin is synthesized
in hepatocytes and secreted to the bloodstream for binding to the iron exporter ferroportin (FPN)
in target cells, primarily macrophages and enterocytes, and to some extent hepatocytes (Figure 1).
The binding of hepcidin promotes internalization and lysosomal degradation of ferroportin
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FIGURE 1 | Distribution of iron in the adult human body and regulation of iron traffic. Circulating iron is bound to transferrin (holo-Tf) and delivered to tissues
(black arrows). Holo-Tf is primarily replenished by iron recycled from tissue macrophages (thick red arrow), but also by dietary iron absorbed by duodenal enterocytes
(thin red arrow). Under conditions of iron deficiency, iron stored in hepatocytes can also be mobilized (thin red arrow). Iron efflux to the bloodstream is inhibited by the
liver-derived peptide hormone hepcidin, which binds to the iron exporter ferroportin (FPN) and promotes its degradation.
(Drakesmith et al., 2015). As a result, recycled iron remains in
macrophages, while dietary iron absorption through the intestine
is inhibited.
Hepcidin expression is predominantly modulated by iron,
inflammation and erythropoiesis (Figure 2), but also responds
to other stimuli such as endoplasmic reticulum stress, oxidative
stress, gluconeogenesis, gonadal hormones, growth factors and
hypoxia (Ganz and Nemeth, 2015; Kim and Nemeth, 2015;
Pietrangelo, 2016; Wang and Babitt, 2016). Increased serum
or tissue iron levels (reflected in transferrin saturation or
expression of hepatic BMP6, respectively) promote hepcidin
induction via BMP/SMAD signaling. Inflammatory IL-6 triggers
hepcidin induction via IL-6/STAT signaling, in crosstalk with
the BMP/SMAD pathway. Activin B is another inflammatory
cytokine that activates hepcidin via non-canonical BMP/SMAD
signaling. Increased erythropoietic activity orchestrated by
erythropoietin leads to hepcidin suppression via erythroferrone
(ERFE) and other cytokines. It is not well understood how ERFE
suppresses hepcidin, but it appears to attenuate BMP/SMAD
signaling (Nai et al., 2016). Misregulation of hepcidin is
etiologically linked or contributes to iron-related disorders
(listed in Table 1), in which pharmacological targeting of
the hepcidin/ferroportin axis to restore physiological hepcidin
levels is expected to offer therapeutic benefits (Poli et al.,
2014c; Ruchala and Nemeth, 2014; Schmidt and Fleming,
2014; Rochette et al., 2015; Blanchette et al., 2016; Liu et al.,
2016). Pathological implications of hepcidin misregulation are
schematically outlined in Figure 3 and discussed below.
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FIGURE 2 | Major pathways for hepcidin regulation. High serum iron levels or hepatic iron stores (reflected in BMP6) induce hepcidin mRNA transcription via the
BMP/SMAD signaling cascade. The inflammatory cytokines IL-6 and activin B induce hepcidin mRNA transcription via JAK/STAT and non-canonical BMP/SMAD
signaling, respectively. High erythropoietic drive (reflected in ERFE) suppresses hepcidin transcription, likely via interference with BMP/SMAD signaling.
DISORDERS OF HEPCIDIN DEFICIENCY
Hereditary hemochromatosis (HH) is an endocrine disorder of
systemic iron overload that is caused by hepcidin insufficiency
(Pietrangelo, 2015; Powell et al., 2016). It constitutes the most
frequent genetic disorder in populations of Northern European
ancestry and is characterized by chronic hyperabsorption of
dietary iron (up to 8–10 mg/day) and unrestricted release of
iron from macrophages. These responses lead to hyperferremia,
gradual saturation of transferrin and buildup of redox-
active non-transferrin bound iron (NTBI), which is deposited
within tissue parenchymal cells. HH patients fail to mount
appropriate iron-dependent hepcidin induction due tomutations
in upstream regulators of iron signaling to hepcidin (HFE,
TfR2 or HJV; see Figure 2) or disruption of the hepcidin gene
(HAMP). Patients with non-classical ferroportin disease, carrying
mutations in ferroportin that prevent hepcidin binding, develop
clinical features of HH due to hepcidin resistance (Mayr et al.,
2010).
HH is genetically heterogeneous and its severity correlates
with the degree of inhibition in hepcidin induction relative
to body iron stores. The prevalent HFE-related variant
exhibits a relatively milder phenotype due to residual hepcidin
responsiveness. Rare variants (TFR2-, HJV- or HAMP-related)
are associated with more profound iron overload and hepcidin
inactivation. Disruption of either HJV or HAMP genes leads to
early onset juvenile HH, the most severe form of the disease.
Clinical complications of adult HH develop after the fourth
decade of life and include liver pathology (fibrosis, cirrhosis,
hepatocellular cancer), diabetes, skin hyperpigmentation,
arthritis and osteoporosis. Juvenile HH patients usually present
with hypogonadism in their early 20s and develop fatal
cardiomyopathy before the age of 30 if untreated. The standard
of care for all forms of HH is reduction of iron burden via
therapeutic phlebotomy (Sivakumar and Powell, 2016). This
approach is effective and cheap. However, some patients are
intolerant, or have low acceptance and compliance to a life-long
treatment, or present contraindications (severe heart disease or
anemia). These patients are good candidates for new therapies
based on restoration of appropriate hepcidin levels.
Hepcidin deficiency is common in hematological disorders
associated with ineffective erythropoiesis, such as thalassemias,
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TABLE 1 | Disorders associated with misregulation of hepcidin.
Disorders with hepcidin deficiency
Hereditary hemochromatosis (genetic suppression of hepcidin)
adult forms caused by mutations in HFE or TFR2
juvenile forms caused by mutations in HJV or HAMP
Iron-loading anemias (erythropoietic suppression of hepcidin)
thalassemias
dyserythropoietic anemias
myelodysplastic syndromes
Chronic liver diseases (suppression of hepcidin by oxidative stress)
chronic hepatitis C
Disorders with hepcidin excess
Anemia of chronic disease (inflammatory induction of hepcidin)
observed in various chronic inflammatory conditions and some cancers
Other anemias with iron-restricted erythropoiesis
Anemia of chronic kidney disease (inflammatory induction and reduced renal
clearance of hepcidin)
Iron-refractory iron deficiency anemia (genetic induction of hepcidin caused
by mutations in TMPRSS6)
Anemia of Castleman disease (inflammatory induction of hepcidin triggered
by tumor-derived IL-6
dyserythropoietic anemias and myelodysplastic syndromes,
and contributes to iron overload (Ginzburg and Rivella,
2011; Camaschella and Nai, 2016). Ineffective erythropoiesis
is characterized by massive expansion of bone marrow
erythroblasts due to decreased production of mature RBCs.
This creates a high demand for iron, which leads to suppression
of hepcidin in spite of systemic iron overload. Evidently, the
negative erythropoietic signals dominate over the positive iron
signals under these conditions. Erythropoietic suppression of
hepcidin triggers iron overload in non-transfused patients with
mild forms of iron loading anemias, and aggravates secondary
iron overload in transfused patients (Ginzburg and Rivella,
2011). Restoration of hepcidin could prevent iron overload in
the former and improve the efficacy of iron chelation therapy in
the latter.
Inhibition of hepcidin expression also contributes to iron
overload observed in chronic hepatitis C and other chronic liver
diseases (Sebastiani and Pantopoulos, 2011; Pietrangelo, 2016).
This is mainly attributed to oxidative stress mechanisms, which
appear to override hepcidin-inducing inflammatory signals.
Eradication of hepatitis C virus with direct-acting antiviral
(DAA) drugs (Zopf et al., 2016) is expected to restore hepcidin
expression without need for further interventions.
DISORDERS OF HEPCIDIN EXCESS
Excessive hepcidin expression is commonly observed in chronic
inflammatory conditions due to infectious or autoimmune
disorders or cancer (Weiss, 2015; Wang and Babitt, 2016).
Inflammatory induction of hepcidin is primarily mediated by
IL-6 and leads to hypoferremia due to ferroportin degradation
and iron sequestration in tissue macrophages. Remodeling of
iron metabolism by hepcidin-independent mechanisms may
further exacerbate this phenotype. Thus, lipopolysaccharide
(LPS) and interferon-γ (IFN-γ) inhibit iron eﬄux from
monocytes by decreasing ferroportin expression (Ludwiczek
et al., 2003), while the Toll-like receptor 2 and 6 (TLR2/6) ligands
FSL1 or PAM3CSK4 trigger hypoferemia in mice by suppressing
ferroportin transcription in tissue macrophages (Guida et al.,
2015).
The acute hypoferremic response is considered to be
protective against infection by depriving bacteria from iron,
and may also be enhanced by antimicrobial activities of
hepcidin. However, persistent chronic hypoferremia restricts
iron availability for erythropoiesis (Ganz and Nemeth, 2015).
Together with immune-driven reduced proliferation and
life span of RBCs, the diversion of iron traffic contributes
to pathogenesis of the anemia of chronic disease (ACD),
or anemia of inflammation, the most frequent anemia
among hospitalized patients (Weiss, 2015). ACD is typically
normocytic/normochromic and unassociated with a reduction in
body iron stores, but may be confounded by true iron deficiency
due to chronic blood losses and/or scarcity or malabsorption
of dietary iron. ACD patients with true iron deficiency
exhibit reduced hepcidin levels and a microcytic/hypochromic
phenotype.
Correction of ACD improves quality of patients’ life. The best
strategy is the successful treatment of the primary underlying
cause. When this is not possible, ACD is often managed with
erythropoiesis-stimulating agents (ESAs), combined or not with
oral or intravenous iron administration or RBC transfusions.
Nevertheless, these approaches are not always efficacious because
hepcidin overexpression blunts responses to ESAs and maintains
iron unavailable to erythroblasts. Therefore, they could be
complemented by strategies to lower hepcidin levels, thereby
mitigating erythropoietic iron-restriction.
Patients with chronic kidney disease (CKD) accumulate
high hepcidin levels in the bloodstream due to reduced renal
clearance, but also due to inflammatory induction of hepcidin
transcription (Tsuchiya and Nitta, 2013). This is associated
with iron-restricted erythropoiesis and contributes to anemia.
Moreover, it negatively affects therapy with ESAs and oral
or intravenous iron. Thus, hepcidin-lowering strategies could
improve therapeutic outcomes.
Genetic inactivation of the TMPRSS6 gene leads to
unrestricted hepcidin production in spite of low body iron
stores, which underlies the pathogenesis of iron-refractory
iron deficiency anemia (IRIDA) (Heeney and Finberg, 2014).
TMPRSS6 encodes matriptase-2, a transmembrane serine
protease that negatively regulates BMP/SMAD signaling to
hepcidin (see Figure 2). It appears that hepcidin overexpression
is the sole driver of IRIDA, which is microcytic and hypochromic.
High hepcidin levels render IRIDA patients unresponsive to
oral and partially responsive to intravenous iron therapy.
Here, correction of hepcidin excess would not only improve
responsiveness to iron therapy, but also provide an etiologic
cure.
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FIGURE 3 | Imbalance in hepcidin expression. Physiological hepcidin responses correlate with healthy body iron metabolism. Pathologically low hepcidin
expression occurs in hereditary hemochromatosis (HH) and in iron-loading anemias; this leads to hyperferremia and parenchymal tissue iron overload due to increased
iron efflux to the bloodstream from macrophages and intestinal enterocytes. Pathologically high hepcidin expression occurs in the anemia of chronic disease (ACD) and
other anemias of iron-restricted erythropoiesis; this leads to hypoferremia and decreased iron availability for erythropoiesis due to iron sequestration in macrophages.
Pediatric patients with Castleman disease develop a chronic
inflammatory anemia with IRIDA-like features. Castleman
disease is caused by tumors overproducing IL-6, which in
turn promotes an inflammatory state and excessive hepcidin
expression (Arlet et al., 2010). The ensuing anemia is refractory to
oral iron therapy and can be reversed by resection of the tumor,
which eliminates the hepcidin inducer (IL-6). Pharmacological
reduction of hepcidin could offer another option for anemia
management.
All above-described conditions constitute disorders of
systemic hepcidin excess, where high circulating hepcidin
levels are derived from hepatocytes. Nevertheless, different
cell types in several tissues can also produce hepcidin
locally, and this may have profound pathophysiological
ramifications. For instance, hepcidin generated by breast or
prostate cancer epithelial cells promotes iron retention via
autocrine degradation of ferroportin, which in turn favors
survival and growth (Pinnix et al., 2010; Tesfay et al., 2015).
Therefore, targeted delivery of hepcidin antagonists to hepcidin-
overexpressing tumors may sensitize them to anti-cancer
therapies.
Hepcidin is also produced in response to inflammation or
other signals by heart cardiomyocytes (Merle et al., 2007) and by
brain astrocytes and microglia (Urrutia et al., 2013). Considering
that the hepcidin/ferroportin axis is crucial for cardiac function
(Lakhal-Littleton et al., 2015) and that inflammatory induction
of hepcidin causes iron accumulation in nervous system cells
(Urrutia et al., 2013), localized targeting of hepcidin excess in the
heart or brain may be important in the context of cardiovascular
or neurodegenerative disorders.
PHARMACOLOGICAL RESTORATION OF
HEPCIDIN
The therapeutic potential of restoring hepcidin levels in
iron overload states is highlighted by genetic studies in
mice. Thus, transgenic expression of hepcidin prevented iron
overload in Hfe−/− (Nicolas et al., 2003) and Hbbth3/+
(Gardenghi et al., 2010) mice, models of HH and β-thalassemia
intermedia, respectively. Likewise, genetic disruption of Tmprss6
enhanced BMP/SMAD signaling, increased endogenous hepcidin
expression and prevented iron overload in Hfe−/− (Finberg
et al., 2011) and Hbbth3/+ mice (Nai et al., 2012). Moreover,
manipulation of hepcidin levels by these strategies also improved
erythropoiesis in Hbbth3/+ mice (Gardenghi et al., 2010; Nai
et al., 2012). It should be noted that disruption of both Tmprss6
alleles offered optimal correction of iron overload but also
caused microcytic anemia in Hfe−/− mice (Finberg et al., 2011),
suggesting that titration of hepcidin levels within a physiological
window is imperative to prevent adverse effects of hepcidin
excess.
The protective effects of Tmprss6 ablation in the Hfe−/−
and Hbbth3/+ backgrounds rendered this gene a candidate
Frontiers in Pharmacology | www.frontiersin.org 5 June 2016 | Volume 7 | Article 160
Sebastiani et al. Hepcidin Therapeutics
pharmacological target for therapeutic hepcidin induction. In
fact, suppression of hepatic Tmprss6 by using RNAi (Schmidt
et al., 2013) or antisense oligonucleotides (Guo et al., 2013a)
increased hepcidin expression in wild type, Hfe−/− andHbbth3/+
mice. Importantly, it reduced systemic iron overload in Hfe−/−
and Hbbth3/+ mice, and ameliorated anemia in Hbbth3/+ mice.
The development of oligonucleotide therapeutics against target
genes in the liver is an active area of research (Sehgal et al., 2013).
Limitations are related to potential off-target effects and toxicity,
pharmacokinetic problems of delivery and clearance from the
bloodstream, as well as high cost.
Administration of recombinant BMP6 was shown to improve
iron signaling to hepcidin and correct systemic iron homeostasis
in Hfe−/− mice, even though endogenous BMP6 expression is
appropriately induced in these animals (Corradini et al., 2010).
Nevertheless, prolonged BMP6 application caused peritoneal
calcifications, indicative of lack of target specificity, which may
lead to further pleiotropic side effects.
Cell culture studies and chemical screens identified several
small molecules capable of stimulating hepcidin transcription
in vitro, such as genistein (Zhen et al., 2013), SB204741,
daunorubicin, ethacridine, phenazopyridine, 9-aminoacridine,
amlexanox, lansoprazole, leflunomide, ipriflavone, AS252424,
pterostilbene, AG1296, GTP14564, SU6668, leflunomide, 10058-
F4 and vorinostat (Gaun et al., 2014). An RNAi screen
identified sorafenib, wortmannin, rapamycin and metformin
as inducers of hepcidin mRNA expression (Mleczko-Sanecka
et al., 2014). These drugs affect different pathways, including
growth factor signaling, anti-inflammatory signaling, DNA
repair and apoptosis. Their exact mechanisms of action are
not well understood and their capacity to control hepcidin
expression in vivo has not been examined. Broad target
specificity may disqualify many of the above-described drugs for
pharmacological applications to stimulate hepcidin.
Another small molecule screen identified three steroid
molecules as hepcidin inducers (Li et al., 2016). Progesterone,
epitiostanol, and mifepristone were shown to stimulate hepcidin
transcription independently of the BMP/SMAD and IL-6/STAT3
pathways, by a mechanism requiring progesterone receptor
membrane component-1 (PGRMC1). Administration of
progesterone to women in the context of standard fertility
treatments resulted in hepcidin induction (Li et al., 2016).
Contrary to progesterone, 17β-estradiol inhibits hepcidin
transcription via an estrogen-responsive promoter element
(Yang et al., 2012). Testosterone likewise inhibits hepcidin but
operates by enhancing negative epidermal growth factor receptor
(EGFR) signaling (Latour et al., 2014), and by competing
positive BMP signaling via androgen receptor binding to SMAD
proteins (Guo et al., 2013b). Hepcidin-inducing steroids or drugs
that lower 17β-estradiol or testosterone could be applied for
pharmacological restoration of hepcidin. Nevertheless, potential
long-term side effects of steroids should be considered.
Hepcidin supplementation therapy would provide a
straightforward approach, devoid of inherent limitations
associated with the targeting of upstream regulators. However,
the chemical synthesis of hepcidin or its expression as
recombinant peptide is costly, while appropriate folding to
the biologically active form is complicated by the presence of 8
cysteine residues within the 25 amino acids of the mature peptide
forming 4 disulfide bridges (Figure 4). Moreover, synthetic or
recombinant hepcidin is rapidly cleared in the circulation and
therefore pharmacological concentrations cannot be sustained.
Encapsulation of hepcidin into biocompatible nanocarriers
suitable for controlled release of therapeutics (Cheng et al., 2015)
could theoretically address this issue. A formulation of hepcidin
developed by La Jolla Pharmaceutical Company (LJPC-401) is
currently undergoing Phase 1 clinical trials with patients at risk
of iron overload (http://lajollapharmaceutical.com/2015/10/la-
jolla-pharmaceutical-company-doses-first-patient-in-phase-1-
clinical-trial-of-ljpc-401-in-patients-at-risk-of-iron-overload/).
Biochemical studies revealed that hepcidin interacts with
ferroportin via its N-terminal region (highlighted in Figure 4),
and that C-terminal amino acid residues are dispensable. This
led to the development of mini-hepcidin analogs containing
a minimal core of 7–9 N-terminal amino acids with a single
cysteine, which suffice to trigger ferroportin internalization and
degradation in cells and mice (Preza et al., 2011). Substitution
of natural with modified amino acids and introduction of
polyethylene glycol (PEG) and hydrophobic linkers (palmitic
acid) improved stability and pharmacological properties of mini-
hepcidins. Cyclization may increase stability but appears to
reduce biological activity (Chua et al., 2015). Treatment with
an engineered mini-hepcidin mimetic (PR65) prevented iron
overload in iron-depleted hepcidin-deficient Hamp−/− mice,
FIGURE 4 | Crystal structure and sequence of human hepcidin. The nine
N-terminal amino acids involved in binding to ferroportin are highlighted in
yellow (PDB ID 1M4F). Disulfide bonds are highlighted in orange.
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but was less efficient in correcting iron traffic when these
mice were already iron overloaded (Ramos et al., 2012). High
doses of PR65 caused anemia, emphasizing the importance of
titration. The mini-hepcidin pro-drug M009 is metabolized to
active mini-hepcidin M004 and was recently shown to improve
erythropoiesis in Hbbth3/+ mice and in a mouse model of
polycythemia vera (Casu et al., 2016). Another mini-hepcidin
derivative developed by Merganser Biotech (M012) initiated a
clinical trial in February 2016 (http://merganserbiotech.com/
2016/02/24/merganser-biotech-inc-initiates-first-clinical-trial/).
Interestingly, administration of the mini-hepcidin mimetic
PR73 protected Hamp−/− mice against infection with the
siderophilic bacterium Vibrio vulnificus (Arezes et al., 2015).
PR73 caused hypoferremia to these animals in spite of tissue
iron overload, which restricted circulating iron fromV. vulnificus
and thereby inhibited its growth. Considering that infections
with extracellular siderophilic pathogens can be lethal to HH
patients (Frank et al., 2011), these data highlight another possible
application of hepcidin agonists. Finally, the adverse effects of
hepcidin inactivation in mouse models of malaria infection
(Portugal et al., 2011) or microbial sepsis suggest a therapeutic
potential of hepcidin agonists in the context of these pathologies
(Zeng et al., 2015).
PHARMACOLOGICAL REDUCTION OF
HEPCIDIN
Targeting of hepcidin pathways is expected to correct defects
triggered by excessive hepcidin expression. Supporting evidence
is provided by studies with multicentric Castleman disease
patients who were treated with therapeutic monoclonal
antibodies against IL-6 receptor (tocilizumab) or IL-6
(siltuximab). These treatments reduced hepcidin levels and
improved anemia (Song et al., 2010; Casper et al., 2015).
Tocilizumab administration also lowered hepcidin and improved
anemia in rheumatoid arthritis patients (Isaacs et al., 2013; Song
et al., 2013) and in a monkey arthritis model (Hashizume et al.,
2010). Similar results were obtained when rheumatoid arthritis
patients were treated with antibodies against TNFα (golimumab
or infliximab), possibly as an indirect result of concomitant
suppression of IL-6 (Doyle et al., 2013; Song et al., 2013).
Studies with cell and mouse models showed that downstream
inhibition of the IL-6/STAT3 signaling pathway by using small
molecule inhibitors of STAT3 (curcumin, AG490 and PpYLKTK)
likewise decreases hepcidin (Jiao et al., 2009; Fatih et al., 2010;
Zhang et al., 2011). However, further development of this class
of drugs as hepcidin inhibitors is hindered by lack of specificity
(all STAT3 inhibitors), competing iron chelating properties
(curcumin) or poor pharmacokinetics (AG490 and PpYLKTK).
As the IL-6/STAT3 and BMP/SMAD signaling pathways are
tightly connected (Wang and Babitt, 2016), targeting the latter
has the potential to efficiently antagonize hepcidin induction
under inflammatory conditions. One strategy exploited the
high affinity of BMPs to heparin, a glycosaminoglycan that is
clinically applied as anticoagulant. Thus, heparin was shown to
inhibit hepcidin expression in cells and mice by sequestering
BMPs, while patients treated with heparin for prevention of
deep vein thrombosis had reduced serum hepcidin levels (Poli
et al., 2011). Because the anticoagulant properties of heparin
are undesired for interventions to reduce hepcidin excess,
glycol-split non-anticoagulant heparins were tested and found
to be equally effective as hepcidin inhibitors; moreover they
improved anemia in mouse models of inflammation (Poli et al.,
2014a). Highly sulfated heparins with low anticoagulant activity
likewise inhibited hepcidin in cells and mice (Poli et al., 2014b).
Preservation of high sulfation grade and molecular weight are
critical for their hepcidin inhibitory activity (Asperti et al., 2016).
Glycol-split and highly sulfated heparins are good candidates
for pharmacological targeting of hepcidin in clinical settings and
are amenable to further development. Their efficacy and safety
profile needs to be established in randomized controlled trials.
HJV is a BMP co-receptor that enhances iron signaling
to hepcidin (Babitt et al., 2006). Its neutralization by using
humanized monoclonal HJV antibodies (developed by
Abbvie) reduced hepcidin expression in rats and cynomolgus
monkeys (Böser et al., 2015). Moreover, they corrected
anemia via hepcidin inhibition in rat and mouse models
of ACD, and in Tmprss6−/− mice (Kovac et al., 2016). A
secreted soluble HJV form (sHJV) functions as a competitive
inhibitor of BMP binding to BMP receptors (Lin et al.,
2005). Administration of sHJV.Fc, a fusion of sHJV with
the Fc fragment of immunoglobulin G, reduced hepcidin
and ameliorated anemia in a rat model of ACD (Theurl
et al., 2011). Two clinical trials sponsored by Ferrumax
Pharmaceuticals Inc aimed to use sHJV.Fc (FMX-8) for
the treatment of patients with renal disease, but were not
completed due to inability to recruit patients meeting eligibility
criteria (ClinicalTrials.gov Identifiers: NCT01873534 and
NCT02228655).
Preliminary data of hepcidin inhibition by targeting upstream
regulators of the BMP/SMAD and IL-6/STAT3 pathways with
oligonucleotide therapeutics were reported a few years ago
(Akinc et al., 2011), but the current stage of development of these
technologies is unknown.
Small molecule inhibitors of the BMP/SMAD pathway have
been tested and shown to act as hepcidin-lowering agents. Thus,
dorsomorphin, an inhibitor of the type I BMP receptors ALK2,
ALK3, and ALK6, prevented hepcidin induction by IL-6 in cells
and induced hyperferremia due to hepcidin suppression in mice
(Yu et al., 2008). Furthermore, the dorsomorphin derivative
LDN-193189, antagonized inflammatory induction of hepcidin
in cells and mitigated anemia in rat (Theurl et al., 2011) and
mouse (Steinbicker et al., 2011; Mayeur et al., 2015) models
of ACD, and in a rat model of kidney disease (Sun et al.,
2013). Interestingly, suppression of hepcidin by LDN-193189
was associated with anti-atherogenic responses in apoE−/−
mice, which were reversed by exogenous hepcidin (Saeed et al.,
2012). These findings suggest that pharmacological targeting
of hepcidin may be valuable beyond the context of improving
erythropoiesis. Nevertheless, dorsomorphin and LDN-193189
are unlikely to be considered for clinical application due to
lack of target specificity (Boergermann et al., 2010). TP-0184, a
specific ALK2 inhibitor developed by Tolero Pharmaceuticals,
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was recently shown to block inflammatory induction of hepcidin
in mouse models of ACD and cancer-induced anemia (Peterson
et al., 2015). Further studies are required to assess its suitability
for clinical applications.
Anemia in elderly persons with chronic inflammatory
conditions (Perlstein et al., 2011) and in CKD patients
(Zughaier et al., 2014), is often associated with vitamin D
deficiency. Biochemical studies showed that binding of 1,25-
dihydroxy-vitamin D to its receptor directly suppresses hepcidin
transcription by binding to a promoter element (Bacchetta
et al., 2014). Importantly, pilot clinical studies demonstrated
that vitamin D supplementation can decrease hepcidin levels
in healthy volunteers (Bacchetta et al., 2014) and early stage
CKD patients (Zughaier et al., 2014). These findings underline
the potential pharmacological value of vitamin D as a hepcidin-
lowering agent, which needs to be further explored in animal
models and randomized controlled trials.
Direct inhibition of hepcidin by neutralizing antibodies
or other inhibitory molecules offers further opportunities
for mitigating the adverse effects of hepcidin overexpression.
Neutralizing hepcidin antibodies were shown to modulate iron
metabolism in mice and cynomolgus monkeys; moreover, they
improved erythropoiesis and responses to ESA therapy in mouse
models of ACD (Sasu et al., 2010; Cooke et al., 2013). LY2787106,
a monoclonal hepcidin antibody developed by Eli Lily and
Company was evaluated in a Phase 1 clinical trial in patients
with cancer-associated anemia (ClinicalTrials.gov Identifier:
NCT01340976). The antibody treatment was well tolerated and
resulted in transient iron mobilization and increased reticulocyte
count relative to baseline (Vadhan-Raj et al., 2015).
Neutralization of hepcidin is also possible by using relatively
high molecular weight antagonists. Pieris Pharmaceuticals
Inc generated PRS-080, a PEGylated anticalin protein that
specifically binds to hepcidin and inhibits its activity. Following
successful initial testing in vitro and in mice (Hohlbaum et al.,
2011), the pharmacokinetic properties and safety profile of PRS-
080 were assessed in a clinical trial with healthy volunteers
(ClinicalTrials.gov Identifier: NCT02340572). The results were
encouraging and a further trial is planned with anemic CKD
patients (Moebius et al., 2015).
TABLE 2 | Hepcidin inducers and mimetics validated in vivo.
Drug Target Reference
recombinant BMP6 BMPRs Corradini et al., 2010
RNAi Tmprss6 Schmidt et al., 2013
antisense oligonucleotides Tmprss6 Guo et al., 2013a
progesterone PGRMC1 Li et al., 2016
LJPC-401 (hepcidin
formulation)
FPN La Jolla Pharmaceutical Company
(http://www.lajollapharmaceutical.com)
PR65 (mini-hepcidin) FPN Ramos et al., 2012
M009 (pro-M004) M004
(mini-hepcidin)
FPN Casu et al., 2016
M012 (mini-hepcidin) FPN Merganser Biotech (http://www.
merganserbiotech.com)
PR73 (mini-hepcidin) FPN Arezes et al., 2015
NOXXON Pharma AG generated NOX-H94 (Lexaptepid
Pegol), a Spiegelmer hepcidin antagonist. This PEGylated non-
natural mirror-image L-oligoribonucleotide binds with high
affinity to hepcidin and operates as a specific inhibitor. NOX-
H94 administration improved inflammation-related anemia
in cynomolgus monkeys (Schwoebel et al., 2013). Moreover,
NOX-H94 prevented hypoferremia in experimental human
endotoxemia with LPS-injected volunteers (Van Eijk et al.,
2014) (ClinicalTrials.gov Identifier: NCT01522794). NOX-H94
is currently being evaluated in another three Phase 1 and
Phase 2 clinical trials on patients with cancer-related anemia,
ACD or CKD (ClinicalTrials.gov Identifiers: NCT01691040,
NCT01372137, and NCT02079896).
A chemical screen for small molecule hepcidin antagonists
identified fursultiamine, a thiol-reactive thiamine derivative
that binds to ferroportin on C326 and thereby precludes the
binding of hepcidin (Fung et al., 2013). This drug is available
over-the-counter for treating vitamin B1 deficiency. While it
efficiently protected ferroportin against hepcidin in cultured
cells, it failed to exhibit in vivo anti-hepcidin activity, possibly
due to rapid plasma turnover. These results suggest that
fursultiamine could only be further considered as a hepcidin-
lowering agent if modified to stable derivatives, or delivered
TABLE 3 | Hepcidin antagonists validated in vivo.
Drug Target Reference
Tocilizumab (monoclonal
IL-6 receptor Ab)
IL-6 receptor Song et al., 2010
Siltuximab (monoclonal
IL-6 Ab)
IL-6 Casper et al., 2015
Curcumin STAT3 Jiao et al., 2009
AG490 (small molecule) JAK2 Zhang et al., 2011
Heparin BMPs Poli et al., 2011
glycol-split heparins BMPs Poli et al., 2014a
highly sulfated heparins BMPs Poli et al., 2014b
monoclonal HJV Ab HJV Abbvie (www.abbvie.com)
sHJV.Fc BMPs Theurl et al., 2011
Dorsomorphin (small
molecule)
type I BMPRs Yu et al., 2008
LDN-193189 (small
molecule)
type I BMPRs Steinbicker et al., 2011
TP-0184 (small molecule) ALK2 Tolero Pharmaceuticals
(www.toleropharma.com)
1,25-dihydroxy-vitamin D Vitamin D receptor Bacchetta et al., 2014
17β–estradiol estrogen-responsive
promoter
Yang et al., 2012
Testosterone EGFR Latour et al., 2014
LY2787106 (monoclonal
hepcidin Ab)
Hepcidin Eli Lily and Company
(www.lilly.com)
PRS-808 (PEGylated
anticalin)
Hepcidin Pieris Pharmaceuticals Inc
(www.pieris.com)
NOX-H94 (PEGylated
Spiegelmer)
Hepcidin Schwoebel et al., 2013
NOXXON Pharma AG
(www.noxxon.com)
LY2928057 (monoclonal
FPN Ab)
FPN Witcher et al., 2013 Eli Lily
and Company (www.lilly.com)
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in formulations that enable sustained controlled release.
Nevertheless, they also show that blocking the hepcidin-binding
site of ferroportin offers another option for pharmacological
targeting the hepcidin/ferroportin axis. Along these lines,
Eli Lily and Company developed a monoclonal ferroportin
antibody (LY2928057), which increased iron mobilization in
cynomolgus monkeys by binding to ferroportin and thereby
inhibiting access to hepcidin (Witcher et al., 2013). LY2928057
is currently being evaluated in two Phase 1 clinical trials with
healthy volunteers and anemic CKD patients (ClinicalTrials.gov
Identifiers: NCT01330953 and NCT01991483).
CONCLUSIONS
Hepcidin is a master hormonal regulator of systemic iron
homeostasis. Under physiological conditions, its expression
remains within a relatively narrow window. Misregulation of
hepcidin is associated with a broad spectrum of disorders
ranging from iron overload states to anemias with iron-restricted
erythropoiesis. Correction of hepcidin levels can provide an
etiologic cure to some of these disorders (HH, IRIDA), or
offer therapeutic benefits to others (thalassemia, ACD). Several
agonists and antagonists of hepcidin have been developed. The
ones that have been validated in preclinical or clinical settings
are summarized in Table 2 (inducers/mimetics) and Table 3
(antagonists). These drugs act at different levels through the
hepcidin/ferroportin axis. Promising candidates are currently
being further evaluated in randomized controlled trials. A
major challenge for using hepcidin therapeutics is to maintain
physiological concentrations of circulating hepcidin, and thereby
avoid a shift from hepcidin deficiency to excess and vice
versa.
AUTHOR CONTRIBUTIONS
GS and NW contributed to writing the manuscript. KP wrote the
manuscript.
ACKNOWLEDGMENTS
Supported by a grant from the Canadian Institutes for Health
Research (CIHR; MOP-86514).
REFERENCES
Akinc, A., Chan-Daniels, A., Sehgal, A., Foster, D., Bettencourt, B. R., Hettinger,
J., et al. (2011). “Targeting the hepcidin pathway with RNAi therapeutics for
the treatment of Anemia,” in 53th Annual Meeting of the American Society for
Hematology (ASH) (San Diego, CA), Abstract 688.
Arezes, J., Jung, G., Gabayan, V., Valore, E., Ruchala, P., Gulig, P. A., et al. (2015).
Hepcidin-induced hypoferremia is a critical host defense mechanism against
the siderophilic bacterium Vibrio vulnificus. Cell Host Microbe 17, 47–57. doi:
10.1016/j.chom.2014.12.001
Arlet, J. B., Hermine, O., Darnige, L., Ostland, V., Westerman, M., Badoual,
C., et al. (2010). Iron-deficiency anemia in Castleman disease: implication
of the interleukin 6/hepcidin pathway. Pediatrics 126, e1608– e1612. doi:
10.1542/peds.2010-1123
Asperti, M., Naggi, A., Esposito, E., Ruzzenenti, P., Di Somma, M., Gryzik,
M., et al. (2016). High sulfation and a high molecular weight are
important for anti-hepcidin activity of heparin. Front. Pharmacol. 6:316. doi:
10.3389/fphar.2015.00316
Babitt, J. L., Huang, F. W., Wrighting, D. M., Xia, Y., Sidis, Y., Samad, T.
A., et al. (2006). Bone morphogenetic protein signaling by hemojuvelin
regulates hepcidin expression. Nat. Genet. 38, 531–539. doi: 10.1038/n
g1777
Bacchetta, J., Zaritsky, J. J., Sea, J. L., Chun, R. F., Lisse, T. S., Zavala, K., et al. (2014).
Suppression of iron-regulatory hepcidin by vitamin D. J. Am. Soc. Nephrol. 25,
564–572. doi: 10.1681/ASN.2013040355
Blanchette, N. L., Manz, D. H., Torti, F. M., and Torti, S. V. (2016). Modulation of
hepcidin to treat iron deregulation: potential clinical applications. Expert Rev.
Hematol. 9, 169–186. doi: 10.1586/17474086.2016.1124757
Boergermann, J. H., Kopf, J., Yu, P. B., and Knaus, P. (2010). Dorsomorphin and
LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12
cells. Int. J. Biochem. Cell Biol. 42, 1802–1807. doi: 10.1016/j.biocel.2010.07.018
Böser, P., Seemann, D., Liguori, M. J., Fan, L., Huang, L., Hafner, M., et al. (2015).
Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron
in rats and cynomolgus monkeys by hepcidin downregulation. AAPS J. 17,
930–938. doi: 10.1208/s12248-015-9770-4
Camaschella, C., and Nai, A. (2016). Ineffective erythropoiesis and regulation
of iron status in iron loading anaemias. Br. J. Haematol. 172, 512–523. doi:
10.1111/bjh.13820
Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., et al. (2015).
Analysis of inflammatory and anemia-related biomarkers in a randomized,
double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal
Antibody) in patients with multicentric castleman disease. Clin. Cancer Res. 21,
4294–4304. doi: 10.1158/1078-0432.CCR-15-0134
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., et al.
(2016). Minihepcidin peptides as disease modifiers in mice affected by beta-
thalassemia and polycythemia vera. Blood. doi: 10.1182/blood-2015-10-676742.
[Epub ahead of print].
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., and Saltzman, W. M. (2015). A
holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev.
Drug Discov. 14, 239–247. doi: 10.1038/nrd4503
Chua, K., Fung, E., Micewicz, E. D., Ganz, T., Nemeth, E., and Ruchala, P. (2015).
Small cyclic agonists of iron regulatory hormone hepcidin. Bioorg. Med. Chem.
Lett. 25, 4961–4969. doi: 10.1016/j.bmcl.2015.03.012
Cooke, K. S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami,
P., et al. (2013). A fully human anti-hepcidin antibody modulates iron
metabolism in both mice and nonhuman primates. Blood 122, 3054–3061. doi:
10.1182/blood-2013-06-505792
Corradini, E., Schmidt, P. J., Meynard, D., Garuti, C., Montosi, G., Chen, S., et al.
(2010). BMP6 treatment compensates for the molecular defect and ameliorates
hemochromatosis in Hfe knockout mice.Gastroenterology 139, 1721–1729. doi:
10.1053/j.gastro.2010.07.044
Doyle, M. K., Rahman, M. U., Frederick, B., Birbara, C. A., De Vries, D., Toedter,
G., et al. (2013). Effects of subcutaneous and intravenous golimumab on
inflammatory biomarkers in patients with rheumatoid arthritis: results of
a phase 1, randomized, open-label trial. Rheumatology 52, 1214–1219. doi:
10.1093/rheumatology/kes381
Drakesmith, H., Nemeth, E., and Ganz, T. (2015). Ironing out Ferroportin. Cell
Metab. 22, 777–787. doi: 10.1016/j.cmet.2015.09.006
Fatih, N., Camberlein, E., Island,M. L., Corlu, A., Abgueguen, E., Detivaud, L., et al.
(2010). Natural and synthetic STAT3 inhibitors reduce hepcidin expression
in differentiated mouse hepatocytes expressing the active phosphorylated
STAT3 form. J. Mol. Med. 88, 477–486. doi: 10.1007/s00109-009-
0588-3
Finberg, K. E., Whittlesey, R. L., and Andrews, N. C. (2011). Tmprss6 is a
genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood 117,
4590–4599. doi: 10.1182/blood-2010-10-315507
Frank, K. M., Schneewind, O., and Shieh, W. J. (2011). Investigation of a
researcher’s death due to septicemic plague. N. Engl. J. Med. 364, 2563–2564.
doi: 10.1056/NEJMc1010939
Fung, E., Sugianto, P., Hsu, J., Damoiseaux, R., Ganz, T., and Nemeth, E. (2013).
High-throughput screening of small molecules identifies hepcidin antagonists.
Mol. Pharmacol. 83, 681–690. doi: 10.1124/mol.112.083428
Frontiers in Pharmacology | www.frontiersin.org 9 June 2016 | Volume 7 | Article 160
Sebastiani et al. Hepcidin Therapeutics
Ganz, T. (2013). Systemic iron homeostasis. Physiol. Rev. 93, 1721–1741. doi:
10.1152/physrev.00008.2013
Ganz, T., and Nemeth, E. (2015). Iron homeostasis in host defence and
inflammation. Nat. Rev. Immunol. 15, 500–510. doi: 10.1038/nri3863
Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E.,
et al. (2010). Hepcidin as a therapeutic tool to limit iron overload and
improve anemia in beta-thalassemic mice. J. Clin. Invest. 120, 4466–4477. doi:
10.1172/JCI41717
Gaun, V., Patchen, B., Volovetz, J., Zhen, A. W., Andreev, A., Pollastri, M. P.,
et al. (2014). A chemical screen identifies small molecules that regulate hepcidin
expression. Blood Cells Mol. Dis. 53, 231–240. doi: 10.1016/j.bcmd.2014.06.002
Ginzburg, Y., and Rivella, S. (2011). beta-thalassemia: a model for elucidating the
dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood
118, 4321–4330. doi: 10.1182/blood-2011-03-283614
Gkouvatsos, K., Papanikolaou, G., and Pantopoulos, K. (2012). Regulation of iron
transport and the role of transferrin. Biochim. Biophys. Acta 1820, 188–202. doi:
10.1016/j.bbagen.2011.10.013
Guida, C., Altamura, S., Klein, F. A., Galy, B., Boutros, M., Ulmer, A. J., et al.
(2015). A novel inflammatory pathway mediating rapid hepcidin-independent
hypoferremia. Blood 125, 2265–2275. doi: 10.1182/blood-2014-08-595256
Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., et al. (2013a).
Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in
mice. J. Clin. Invest. 123, 1531–1541. doi: 10.1172/JCI66969
Guo, W., Bachman, E., Li, M., Roy, C. N., Blusztajn, J., Wong, S., et al. (2013b).
Testosterone administration inhibits hepcidin transcription and is associated
with increased iron incorporation into red blood cells. Aging Cell 12, 280–291.
doi: 10.1111/acel.12052
Hashizume, M., Uchiyama, Y., Horai, N., Tomosugi, N., and Mihara, M. (2010).
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved
anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
Rheumatol. Int. 30, 917–923. doi: 10.1007/s00296-009-1075-4
Heeney, M. M., and Finberg, K. E. (2014). Iron-Refractory Iron Deficiency
Anemia (IRIDA). Hematol. Oncol. Clin. North Am. 28, 637–652. doi:
10.1016/j.hoc.2014.04.009
Hohlbaum, A. M., Trentman, S., Gille, H., Allesdorfer, A., Belaiba, R. S.,
Huelsmeyer, M., et al. (2011). “Discovery and preclinical characterization of
a novel hepcidin antagonist with tunable PK/PD properties for the treatment
of anemia in different patient populations,” in 53th Annual Meeting of the
American Society for Hematology (ASH) (San Diego, CA), Abstract 687.
Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., and Bernasconi, C. (2013). Effect
of tocilizumab on haematological markers implicates interleukin-6 signalling
in the anaemia of rheumatoid arthritis. Arthritis Res. Ther. 15, R204. doi:
10.1186/ar4397
Jiao, Y., Wilkinson, J. T., Di, X., Wang, W., Hatcher, H., Kock, N. D., et al.
(2009). Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a
biologically active iron chelator. Blood 113, 462–469. doi: 10.1182/blood-2008-
05-155952
Kim, A., and Nemeth, E. (2015). New insights into iron regulation
and erythropoiesis. Curr. Opin. Hematol. 22, 199–205. doi:
10.1097/MOH.0000000000000132
Kovac, S., Boser, P., Cui, Y., Ferring-Appel, D., Casarrubea, D., Huang,
L., et al. (2016). Anti-hemojuvelin antibody corrects anemia caused
by inappropriately high hepcidin levels. Haematologica 101, e173. doi:
10.3324/haematol.2015.140772
Lakhal-Littleton, S., Wolna, M., Carr, C. A., Miller, J. J., Christian, H. C., Ball,
V., et al. (2015). Cardiac ferroportin regulates cellular iron homeostasis and
is important for cardiac function. Proc. Natl. Acad. Sci. U.S.A. 112, 3164–3169.
doi: 10.1073/pnas.1422373112
Latour, C., Kautz, L., Besson-Fournier, C., Island, M. L., Canonne-Hergaux, F.,
Loreal, O., et al. (2014). Testosterone perturbs systemic iron balance through
activation of epidermal growth factor receptor signaling in the liver and
repression of hepcidin. Hepatology 59, 683–694. doi: 10.1002/hep.26648
Li, X., Rhee, D. K., Malhotra, R., Mayeur, C., Hurst, L. A., Ager, E., et al.
(2016). Progesterone receptor membrane component-1 regulates hepcidin
biosynthesis. J. Clin. Invest. 126, 389–401. doi: 10.1172/JCI83831
Lin, L., Goldberg, Y. P., and Ganz, T. (2005). Competitive regulation of hepcidin
mRNA by soluble and cell-associated hemojuvelin. Blood 106, 2884–2889. doi:
10.1182/blood-2005-05-1845
Liu, J., Sun, B., Yin, H., and Liu, S. (2016). Hepcidin: a promising therapeutic
target for iron disorders: a systematic review. Medicine 95, e3150. doi:
10.1097/MD.0000000000003150
Ludwiczek, S., Aigner, E., Theurl, I., and Weiss, G. (2003). Cytokine-mediated
regulation of iron transport in human monocytic cells. Blood 101, 4148–4154.
doi: 10.1182/blood-2002-08-2459
Mayeur, C., Kolodziej, S. A., Wang, A., Xu, X., Lee, A., Yu, P. B., et al. (2015).
Oral administration of a bone morphogenetic protein type I receptor inhibitor
prevents the development of anemia of inflammation. Haematologica 100,
e68–e71. doi: 10.3324/haematol.2014.111484
Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J., Vogel, W., Pietrangelo,
A., et al. (2010). Ferroportin disease: a systematic meta-analysis of clinical
and molecular findings. J. Hepatol. 53, 941–949. doi: 10.1016/j.jhep.2010.
05.016
Merle, U., Fein, E., Gehrke, S. G., Stremmel, W., and Kulaksiz, H. (2007). The iron
regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia
and inflammation. Endocrinology 148, 2663–2668. doi: 10.1210/en.2006-1331
Mleczko-Sanecka, K., Roche, F., Da Silva, A. R., Call, D., D’Alessio, F., Ragab,
A., et al. (2014). Unbiased RNAi screen for hepcidin regulators links hepcidin
suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling.
Blood 123, 1574–1585. doi: 10.1182/blood-2013-07-515957
Moebius, U., Feuerer, W., Fenzl, E., Van Swelm, R., Swinkels, D. W., and
Hohlbaum, A. (2015). “A phase I study investigating the safety, tolerability,
pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist
PRS-080#022. Results from a randomized, placebo controlled, double-blind
study following single administration to healthy subjects,” in 57th Annual
Meeting of the American Society for Hematology (ASH) (Orlando, FL),
Abstract 536.
Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., et al.
(2012). Deletion of TMPRSS6 attenuates the phenotype in a mouse model of
beta-thalassemia. Blood 119, 5021–5029. doi: 10.1182/blood-2012-01-401885
Nai, A., Rubio, A., Campanella, A., Gourbeyre, O., Artuso, I., Bordini, J., et al.
(2016). Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for
erythropoietin-mediated hepcidin suppression in mice. Blood 127, 2327–2336.
doi: 10.1182/blood-2015-11-681494
Nicolas, G., Viatte, L., Lou, D. Q., Bennoun, M., Beaumont, C., Kahn, A., et al.
(2003). Constitutive hepcidin expression prevents iron overload in a mouse
model of hemochromatosis. Nat. Genet. 34, 97–101. doi: 10.1038/ng1150
Papanikolaou, G., and Pantopoulos, K. (2005). Iron metabolism and toxicity.
Toxicol. Appl. Pharmacol. 202, 199–211. doi: 10.1016/j.taap.2004.06.021
Perlstein, T. S., Pande, R., Berliner, N., and Vanasse, G. J. (2011). Prevalence
of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with
anemia: association with anemia of inflammation. Blood 117, 2800–2806. doi:
10.1182/blood-2010-09-309708
Peterson, P. A., Soh, K. K., Lee, Y. S., Kim, W., Whatcott, C. J., Siddiqui-Jain, A.,
et al. (2015). “ALK2 Inhibition via TP-0184 abrogates inflammation-induced
hepcidin expression and is a potential therapeutic for anemia of chronic
disease,” in 57th Annual Meeting of the American Society for Hematology (ASH),
(Orlando, FL), Abstract 273.
Pietrangelo, A. (2015). Genetics, genetic testing, and management of
hemochromatosis: 15 years since hepcidin. Gastroenterology 149, 1240–1251.
doi: 10.1053/j.gastro.2015.06.045
Pietrangelo, A. (2016). Iron and the liver. Liver Int. 36(Suppl. 1), 116–123. doi:
10.1111/liv.13020
Pinnix, Z. K., Miller, L. D., Wang, W., D’agostino, R. Jr., Kute, T., Willingham, M.
C., et al. (2010). Ferroportin and iron regulation in breast cancer progression
and prognosis. Sci. Transl. Med. 2, 43ra56. doi: 10.1126/scitranslmed.3001127
Poli, M., Asperti, M., Naggi, A., Campostrini, N., Girelli, D., Corbella, M., et al.
(2014a). Glycol-split nonanticoagulant heparins are inhibitors of hepcidin
expression in vitro and in vivo. Blood 123, 1564–1573. doi: 10.1182/blood-2013-
07-515221
Poli, M., Asperti, M., Ruzzenenti, P., Mandelli, L., Campostrini, N., Martini,
G., et al. (2014b). Oversulfated heparins with low anticoagulant activity are
strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochem.
Pharmacol. 92, 467–475. doi: 10.1016/j.bcp.2014.09.007
Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., and Arosio, P. (2014c). Hepcidin
antagonists for potential treatments of disorders with hepcidin excess. Front.
Pharmacol. 5:86. doi: 10.3389/fphar.2014.00086
Frontiers in Pharmacology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 160
Sebastiani et al. Hepcidin Therapeutics
Poli, M., Girelli, D., Campostrini, N., Maccarinelli, F., Finazzi, D., Luscieti, S., et al.
(2011). Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo.
Blood 117, 997–1004. doi: 10.1182/blood-2010-06-289082
Portugal, S., Carret, C., Recker, M., Armitage, A. E., Goncalves, L. A., Epiphanio, S.,
et al. (2011). Host-mediated regulation of superinfection in malaria. Nat. Med.
17, 732–737. doi: 10.1038/nm.2368
Powell, L. W., Seckington, R. C., and Deugnier, Y. (2016). Haemochromatosis.
Lancet. doi: 10.1016/S0140-6736(15)01315-X. [Epub ahead of print].
Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., et al. (2011).
Minihepcidins are rationally designed small peptides that mimic hepcidin
activity in mice and may be useful for the treatment of iron overload. J. Clin.
Invest. 121, 4880–4888. doi: 10.1172/JCI57693
Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., et al.
(2012). Minihepcidins prevent iron overload in a hepcidin-deficient mouse
model of severe hemochromatosis. Blood 120, 3829–3836. doi: 10.1182/blood-
2012-07-440743
Rochette, L., Gudjoncik, A., Guenancia, C., Zeller, M., Cottin, Y., and Vergely, C.
(2015). The iron-regulatory hormone hepcidin: a possible therapeutic target?
Pharmacol. Ther. 146, 35–52. doi: 10.1016/j.pharmthera.2014.09.004
Ruchala, P., and Nemeth, E. (2014). The pathophysiology and pharmacology
of hepcidin. Trends Pharmacol. Sci. 35, 155–161. doi: 10.1016/j.tips.2014.
01.004
Saeed, O., Otsuka, F., Polavarapu, R., Karmali, V., Weiss, D., Davis, T., et al. (2012).
Pharmacological suppression of hepcidin increases macrophage cholesterol
eﬄux and reduces foam cell formation and atherosclerosis. Arterioscler.
Thromb. Vasc. Biol. 32, 299–307. doi: 10.1161/ATVBAHA.111.240101
Sasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J.,
et al. (2010). Antihepcidin antibody treatment modulates iron metabolism and
is effective in a mouse model of inflammation-induced anemia. Blood 115,
3616–3624. doi: 10.1182/blood-2009-09-245977
Schmidt, P. J., and Fleming, M. D. (2014). Modulation of hepcidin as
therapy for primary and secondary iron overload disorders: preclinical
models and approaches. Hematol. Oncol. Clin. North Am. 28, 387–401. doi:
10.1016/j.hoc.2013.11.004
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt,
B. R., et al. (2013). An RNAi therapeutic targeting Tmprss6 decreases iron
overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine
beta-thalassemia intermedia. Blood 121, 1200–1208. doi: 10.1182/blood-2012-
09-453977
Schwoebel, F., Van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch,
C., et al. (2013). The effects of the anti-hepcidin Spiegelmer NOX-H94 on
inflammation-induced anemia in cynomolgus monkeys. Blood 121, 2311–2315.
doi: 10.1182/blood-2012-09-456756
Sebastiani, G., and Pantopoulos, K. (2011). Disorders associated with systemic or
local iron overload: from pathophysiology to clinical practice. Metallomics 3,
971–986. doi: 10.1039/c1mt00082a
Sehgal, A., Vaishnaw, A., and Fitzgerald, K. (2013). Liver as a target
for oligonucleotide therapeutics. J. Hepatol. 59, 1354–1359. doi:
10.1016/j.jhep.2013.05.045
Sivakumar, M., and Powell, L. W. (2016). Management of human factors
engineering-associated hemochromatosis: a 2015 update. World J. Hepatol. 8,
395–400. doi: 10.4254/wjh.v8.i8.395
Song, S. N., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., et al.
(2013). Comparative evaluation of the effects of treatment with tocilizumab
and TNF-alpha inhibitors on serum hepcidin, anemia response and disease
activity in rheumatoid arthritis patients. Arthritis Res. Ther. 15, R141. doi:
10.1186/ar4323
Song, S. N., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., and
Yoshizaki, K. (2010). Down-regulation of hepcidin resulting from long-term
treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia
of inflammation in multicentric Castleman disease. Blood 116, 3627–3634. doi:
10.1182/blood-2010-03-271791
Steinbicker, A. U., Sachidanandan, C., Vonner, A. J., Yusuf, R. Z., Deng, D. Y.,
Lai, C. S., et al. (2011). Inhibition of bone morphogenetic protein signaling
attenuates anemia associated with inflammation. Blood 117, 4915–4923. doi:
10.1182/blood-2010-10-313064
Sun, C. C., Vaja, V., Chen, S., Theurl, I., Stepanek, A., Brown, D. E., et al. (2013).
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells
in an adenine-induced kidney disease model of anemia in rats. Nephrol. Dial.
Transplant. 28, 1733–1743. doi: 10.1093/ndt/gfs584
Tesfay, L., Clausen, K. A., Kim, J. W., Hegde, P., Wang, X., Miller, L. D., et al.
(2015). Hepcidin regulation in prostate and its disruption in prostate cancer.
Cancer Res. 75, 2254–2263. doi: 10.1158/0008-5472.CAN-14-2465
Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M.,Willenbacher,W., et al.
(2011). Pharmacologic inhibition of hepcidin expression reverses anemia of
chronic inflammation in rats. Blood 118, 4977–4984. doi: 10.1182/blood-2011-
03-345066
Tsuchiya, K., and Nitta, K. (2013). Hepcidin is a potential regulator of iron
status in chronic kidney disease. Ther. Apher. Dial. 17, 1–8. doi: 10.1111/1744-
9987.12001
Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N. P., Arredondo, M., et al.
(2013). Inflammation alters the expression of DMT1, FPN1 and hepcidin, and
it causes iron accumulation in central nervous system cells. J. Neurochem. 126,
541–549. doi: 10.1111/jnc.12244
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ytiu,
R. V., et al. (2015). “Phase 1 study of a hepcidin antagonist, LY2787106, in
cancer-associated anemia,” in 57th Annual Meeting of the American Society for
Hematology (ASH) (Orlando, FL), Abstract 537.
Van Eijk, L. T., John, A. S., Schwoebel, F., Summo, L., Vauleon, S., Zollner, S.,
et al. (2014). Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-
induced decrease in serum iron in humans. Blood 124, 2643–2646. doi:
10.1182/blood-2014-03-559484
Wang, C. Y., and Babitt, J. L. (2016). Hepcidin regulation in the
anemia of inflammation. Curr. Opin. Hematol. 23, 189–197. doi:
10.1097/MOH.0000000000000236
Weiss, G. (2015). Anemia of chronic disorders: new diagnostic tools
and new treatment strategies. Semin. Hematol. 52, 313–320. doi:
10.1053/j.seminhematol.2015.07.004
Witcher, D. R., Leung, D., Hill, K. A., De Rosa, D. C., Xu, J., Manetta, J., et al.
(2013). “LY2928057, an antibody targeting ferroportin, is a potent inhibitor
of hepcidin activity and increases iron mobilization in normal cynomolgus
monkeys,” in 55th Annual Meeting of the American Society for Hematology
(ASH) (New Orleans, LA), Abstract 3433.
Yang, Q., Jian, J., Katz, S., Abramson, S. B., and Huang, X. (2012). 17beta-Estradiol
inhibits iron hormone hepcidin through an estrogen responsive element half-
site. Endocrinology 153, 3170–3178. doi: 10.1210/en.2011-2045
Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A.,
et al. (2008). Dorsomorphin inhibits BMP signals required for embryogenesis
and ironmetabolism.Nat. Chem. Biol. 4, 33–41. doi: 10.1038/nchembio.2007.54
Zeng, C., Chen, Q., Zhang, K., Chen, Q., Song, S., and Fang, X. (2015).
Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating
host iron status. Anesthesiology 122, 374–386. doi: 10.1097/ALN.000000000
0000466
Zhang, S. P., Wang, Z., Wang, L. X., and Liu, S. J. (2011). AG490: an inhibitor
of hepcidin expression in vivo. World J. Gastroenterol. 17, 5032–5034. doi:
10.3748/wjg.v17.i45.5032
Zhen, A. W., Nguyen, N. H., Gibert, Y., Motola, S., Buckett, P., Wessling-Resnick,
M., et al. (2013). The small molecule, genistein, increases hepcidin expression
in human hepatocytes. Hepatology 58, 1315–1325. doi: 10.1002/hep.26490
Zopf, S., Kremer, A. E., Neurath, M. F., and Siebler, J. (2016). Advances in hepatitis
C therapy: what is the current state - what come’s next? World J. Hepatol. 8,
139–147. doi: 10.4254/wjh.v8.i3.139
Zughaier, S. M., Alvarez, J. A., Sloan, J. H., Konrad, R. J., and Tangpricha, V.
(2014). The role of vitaminD in regulating the iron-hepcidin-ferroportin axis in
monocytes. J. Clin. Transl. Endocrinol. 1, 19–25. doi: 10.1016/j.jcte.2014.01.003
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Sebastiani, Wilkinson and Pantopoulos. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 11 June 2016 | Volume 7 | Article 160
